Valeant Pharmaceuticals Intl Inc. Is Under Scrutiny From the SEC

The list of problems grows for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

The Motley Fool

To say that Monday was chaotic for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) would be a massive understatement.

The mayhem started early in the morning in the wake of Valeant’s decision to delay its fourth-quarter earnings announcement and pull its 2016 guidance. The company’s U.S.-listed shares opened at US$76.52, down 5.1% from the previous close, and continued to trade down from there.

Then later in the morning, Valeant IR vice president Laurie Little emailed a group of sell-side analysts that cover the company, scheduling a call for later in the day. Ms. Little also said not to forward the email to anyone. But when Bloomberg got wind of the call, Ms. Little denied that any call was taking place. She then canceled the call an hour later.

If that wasn’t enough, Moody’s Investor Service put Valeant’s debt under review for a potential downgrade, citing “concerns that Valeant’s underlying operating performance is weaker than Moody’s previous expectations, potentially impeding the company’s deleveraging plans.” This could be a major issue, mainly because the company has over US$30 billion of debt.

But the bad news didn’t stop there. In the afternoon, Valeant confirmed it was under investigation from the Securities and Exchange Commission (SEC). And this latest piece of news sent Valeant’s shares down further–the stock closed at US$65.80 on Monday, down by more than 18%.

In a previous article, I looked at Valeant’s earlier issues. So as a follow up, I’ll take a look at what implications the SEC investigation could have.

Unknown unknowns

Valeant received notice of the SEC’s investigation back in the fourth quarter of 2015, but didn’t disclose it at the time. Fast forward to February 23, and a small outfit called Probes Research said that “new SEC data” was pointing to a possible investigation of Valeant. Then five days later, Probes confirmed that the SEC had launched an investigation. Of course, the press then started asking Valeant questions, and that is why the company acknowledged the investigation on Monday.

Unfortunately, we don’t yet know what the investigation is about. But The Wall Street Journal has reported that it concerns Valeant’s now-terminated relationship with Philidor Rx Services LLC.

If this is true, there is a tremendous amount of downside for Valeant’s stock. The key will be determining just how involved Valeant was in Philidor’s operations and whether or not the company should be held liable for Philidor’s misdeeds. If Valeant is indeed found to be liable, then that could be a catastrophe for shareholders.

Of course, this all remains very speculative. But this is a company facing a number of different investigations, and the news will likely get worse before it gets better. Now is not a good time to buy shares.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »